CA2312188A1 - Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation - Google Patents

Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation Download PDF

Info

Publication number
CA2312188A1
CA2312188A1 CA002312188A CA2312188A CA2312188A1 CA 2312188 A1 CA2312188 A1 CA 2312188A1 CA 002312188 A CA002312188 A CA 002312188A CA 2312188 A CA2312188 A CA 2312188A CA 2312188 A1 CA2312188 A1 CA 2312188A1
Authority
CA
Canada
Prior art keywords
subunit
cytokine
chain
linked
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002312188A
Other languages
French (fr)
Other versions
CA2312188C (en
Inventor
Stephen D. Gillies
Kin-Ming Lo
Yan Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Lexigen Pharmaceuticals Corp.
Stephen D. Gillies
Kin-Ming Lo
Yan Lan
Emd Lexigen Research Center Corp.
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corp., Stephen D. Gillies, Kin-Ming Lo, Yan Lan, Emd Lexigen Research Center Corp., Merck Patent Gmbh filed Critical Lexigen Pharmaceuticals Corp.
Priority to CA2693296A priority Critical patent/CA2693296C/en
Publication of CA2312188A1 publication Critical patent/CA2312188A1/en
Application granted granted Critical
Publication of CA2312188C publication Critical patent/CA2312188C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ration of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.

Claims (24)

1. A heterodimeric fusion protein comprising a first and a second chimeric chain, said first chimeric chain comprising a portion of an Ig heavy chain linked by a peptide bond to a first subunit of a heterodimeric cytokine, said second chimeric chain comprising a portion of an Ig heavy chain linked by a peptide bond to a second subunit of said heterodimeric cytokine, said first and a second chain being linked by a disulfide bond.
2. A fusion protein comprising a first chimeric Ig chain comprising a portion of an Ig heavy chain linked by a peptide bond to a first subunit of a heterodimeric cytokine, said first subunit of said cytokine being linked to a second subunit of said cytokine.
3. The fusion protein of claim 2 further comprising a second chimeric Ig chain comprising a portion of an Ig heavy chain linked by a peptide bond to a first subunit of a heterodimeric cytokine, said first subunit of said cytokine being linked to a second subunit of said cytokine, said first and second chains being linked by a disulfide bond.
4. A trimeric fusion protein comprising a first and a second chimeric chain linked by a disulfide bond, said first chimeric chain comprising a portion of an Ig heavy chain linked by a peptide bond to a first subunit of a heterodimeric cytokine, said second chimeric chain comprising a portion of an Ig heavy chain linked by a peptide bond to a second subunit of said cytokine, said second subunit being linked by a disulfide bond to another said first subunit of said cytokine.
5. A fusion protein .comprising a chimeric Ig chain comprising a portion of an Ig light chain linked by a peptide bond to a first subunit of a heterodimeric cytokine, said first subunit of said cytokine being linked to a second subunit of said cytokine.
6. The fusion protein of claim 1, 2, 3, 4 or 5 wherein said fusion protein displays cytokine biological activity.
7. The fusion protein of claim 1, 2, 3, 4 or 5 wherein said fusion protein displays antigen-binding specificity.
8. The fusion protein of claim 1, 2, 3, 4 or 5 wherein said fusion protein has a longer circulating half life than an unlinked heterodimeric cytokine.
9. The fusion protein of claim 1, 2, 3 or 4 wherein said portion of an Ig heavy chain farther comprises a CH1 domain.
10. The fusion protein of claim 9 wherein said portion of an Ig heavy chain further comprises a CH2 domain.
11. The fusion protein of claim 10 wherein said portion of an Ig heavy chain further comprises a CH3 domain.
12. The fusion protein of claim 1, 2, 3 or 4 wherein said portion of an Ig heavy chain further comprises a CH2 and a CH3 domain.
13. The fusion protein of claim 1, 2, 3, 4 or 5 wherein said heterodimeric cytokine is IL-12.
14. A heterodimeric fusion protein comprising a first and a second chimeric chain, said first chimeric chain comprising an antigen linked to a first subunit of a heterodimeric cytokine, said second chimeric chain comprising an antigen linked to a second subunit of said heterodimeric cytokine, said first and a second chain being linked by a disulfide bond.
15. A fusion protein comprising a first chimeric Ig chain comprising an antigen linked to a first subunit of a heterodimeric cytokine, said first subunit of said cytokine being linked to a second subunit of said cytokine.
16. The fusion protein of claim 15 further comprising a second chimeric Ig chain comprising an antigen linked to a first subunit of a heterodimeric cytokine, said first subunit of said cytokine being linked to a second subunit of said cytokine, said first and second chains being linked by a disulfide bond.
17. A trimeric fusion protein comprising a first and a second chimeric chain linked by a disulfide bond, said first chimeric chain comprising an antigen linked to a first subunit of a heterodimeric cytokine, said second chimeric chain comprising an antigen linked to a second subunit of said cytokine, said second subunit being linked by a disulfide bond to another said fusion subunit of said cytokine.
18. A method of selectively targeting a heterodimeric cytokine, comprising the step of linking at least one subunit of said heterodimeric cytokine by a peptide bond to a portion of an Ig heavy chain, thereby to form a fusion protein displaying binding specificity for a predetermined antigen and cytokine biological activity.
19. A method of selectively targeting a heterodimeric cytokine, comprising the steps of (a) linking a first subunit of said heterodimeric cytokine by a peptide bond to a portion of a first Ig heavy chain, thereby forming a first chimeric chain;
(b) linking a second subunit of said heterodimeric cytokine by a peptide bond to a portion of a second Ig heavy chain, thereby forming a second chimeric chain;
and (c) linking said first and said second chimeric chain by a disulfide bond, thereby forming a heterodimeric fusion protein, said fusion protein displaying binding specificity for a predetermined antigen and cytokine biological activity.
20. A method of selectively targeting a heterodimeric cytokine, comprising the steps of:
(a) linking a first subunit of said heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a first chimeric chain, said first subunit of sand cytokine being linked to a second subunit of said cytokine by a disulfide bond;
(b) linking a lust subunit of said heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a second chimeric chain, said first subunit of said cytokine being linked to a second subunit of said cytokine by a disulfide bond; and (c) linking said first and said second chimeric chain by a disulfide bond, thereby forming a heterodimeric fusion protein, said fusion protein displaying binding specificity for a predetermined antigen and cytokine biological activity.
21. A method of increasing the circulating half-life of a heterodimeric cytokine, comprising the step of linking at least one subunit of said heterodimeric cytokine to a polypeptide, thereby forming a fusion protein having a longer circulating half-life than an unlinked heterodimeric cytokine.
22. The method of claim 21 wherein said polypeptide is selected from the group consisting of a portion of an Ig heavy chain, a portion of an Ig light chain, an antigen, and serum albumin.
23. A method of increasing the circulating half-life a heterodimeric cytokine, comprising the steps of:
(a) linking a first subunit of said heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a first chimeric chain, said first subunit of said cytokine being linked to a second subunit of said cytokine by a disulfide bond;
(b) linking a first subunit of said heterodimeric cytokine by a peptide bond to a polypeptide, thereby forming a second chimeric chain, said first subunit of said cytokine being linked to a second subunit of said cytokine by a disulfide bond; and (c) linking said first and said second chimeric chain by a disulfide bond, thereby forming a heterodimeric fusion protein, said fusion protein having a longer circulating half life than unlinked first and second heterodimeric cytokines.
24. The method of claim 23 wherein said first and second polypeptides are selected from the group consisting of a portion of an Ig heavy chain, a portion of an Ig light chain, an antigen, and serum albumin.
CA2312188A 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation Expired - Lifetime CA2312188C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2693296A CA2693296C (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98699797A 1997-12-08 1997-12-08
US08/986,997 1997-12-08
PCT/US1998/025978 WO1999029732A2 (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2693296A Division CA2693296C (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

Publications (2)

Publication Number Publication Date
CA2312188A1 true CA2312188A1 (en) 1999-06-17
CA2312188C CA2312188C (en) 2010-06-29

Family

ID=25532973

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2312188A Expired - Lifetime CA2312188C (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
CA2693296A Expired - Lifetime CA2693296C (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2693296A Expired - Lifetime CA2693296C (en) 1997-12-08 1998-12-08 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

Country Status (11)

Country Link
US (4) US6838260B2 (en)
EP (2) EP1489100B1 (en)
JP (2) JP4336452B2 (en)
AT (1) ATE267215T1 (en)
AU (1) AU763719B2 (en)
CA (2) CA2312188C (en)
DE (1) DE69824039T2 (en)
DK (1) DK1037927T3 (en)
ES (2) ES2590912T3 (en)
PT (1) PT1037927E (en)
WO (1) WO1999029732A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK1037927T3 (en) * 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (en) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP1187852B1 (en) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (en) * 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
EP1731531B1 (en) 1999-08-09 2012-05-30 Merck Patent GmbH Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
CA2747325A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
BR0112111A (en) * 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
DE60239454D1 (en) 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
JP2005511005A (en) * 2001-07-18 2005-04-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Glycoprotein VI fusion protein
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
PT2829283T (en) * 2003-04-30 2017-09-08 Univ Zuerich Methods for treating cancer using an immunotoxin
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
ES2341126T3 (en) * 2005-05-11 2010-06-15 Philogen S.P.A. L19 ANTIBODY FUSION PROTEIN AGAINST ED-B AND INTERLEUCIN FIBRONECTINE 12.
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
BRPI0620795A2 (en) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschronkter Haftung anti-cd19 antibodies reduced immunogenicity
JP5175214B2 (en) * 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Interleukin-12P40 variant with improved stability
JP5368301B2 (en) * 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス Soluble heterodimeric receptor and uses thereof
CN102405230A (en) 2009-04-22 2012-04-04 默克专利有限公司 Antibody fusion proteins with modified fcrn binding sites
KR20120053042A (en) * 2009-08-17 2012-05-24 로슈 글리카트 아게 Targeted immunoconjugates
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
ES2888249T3 (en) * 2011-10-11 2022-01-03 Univ Zuerich Combination drug comprising IL-12 and an agent for blocking T-cell inhibitory molecules for tumor therapy
CA2925915C (en) 2013-10-02 2023-05-02 Viventia Bio Inc. Anti-epcam antibodies and methods of use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN105543279A (en) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 Preparation method and agent of IL-12/Fc fusion protein with functions of radiation ray injury prevention and treatment and tumor treatment
CN108513547A (en) 2015-03-12 2018-09-07 维文蒂亚生物公司 Therapy for EPCAM positive carcinomas of urinary bladder
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
WO2018030806A1 (en) * 2016-08-10 2018-02-15 아주대학교산학협력단 Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2018297248A1 (en) 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
CN110396133B (en) * 2018-04-25 2021-07-23 免疫靶向有限公司 Fusion protein type prodrug with interleukin 12 as active component
KR20210025054A (en) 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 Heterodimeric proteins and uses thereof
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
PE20211279A1 (en) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc HETERODIMERIC PROTEINS FUSED WITH FC
KR102524247B1 (en) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3 COMPLEX AND USES THEREOF
JP2022536898A (en) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド NOVEL IL-15 PRODRUGS AND METHODS OF USE THEREOF
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
TW202204386A (en) * 2020-04-01 2022-02-01 美商艾希利歐發展股份有限公司 Masked il-12 cytokines and their cleavage products

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3712985A1 (en) 1987-04-16 1988-11-03 Hoechst Ag BIFUNCTIONAL PROTEINS
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (en) * 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3853515T3 (en) 1987-05-21 2005-08-25 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0294703B1 (en) 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
ZA888978B (en) 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (en) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro SPECIFIC MONOCLONAL ANTIBODY FOR A SEQUENCE OF FIBRONETIN EXPRESSED IN TRANSFORMED HYBRID CELLS ACCORDING TO SUCH ANTIBODY AND USE OF THE MONOCLONAL ANTIBODY FOR THE DIAGNOSIS OF TUMORS
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE123065T1 (en) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ATE366311T1 (en) 1989-12-22 2007-07-15 Hoffmann La Roche CYTOTOXIC LYMPHOCYTE MATURATION FACTOR 35KD SUBUNIT AND MONOCLONAL ANTIBODIES SPECIFIC THEREOF
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ATE218889T1 (en) * 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE69227693T2 (en) 1991-08-30 1999-07-22 Hutchinson Fred Cancer Res HYBRID CYTOKINE
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) * 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
PT633929E (en) 1992-04-01 2004-07-30 Merix Bioscience Inc METHOD FOR PROLIFERATION (IN VITRO) OF DENTIFICAL CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENES
EP0615451B1 (en) 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
DE69332485T2 (en) 1992-08-11 2003-11-13 Harvard College Immunomodulatory peptides
DE4228839A1 (en) * 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
CA2147499C (en) 1992-11-05 2010-10-19 Ron S. Israeli Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
HUT73876A (en) * 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
JP3880064B2 (en) 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション Angiostatin and its use in inhibiting angiogenesis
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
DE69523857T2 (en) 1994-09-16 2002-06-13 Merck Patent Gmbh immunoconjugates
JPH11501506A (en) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター Chimeric cytokines and their use
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6169070B1 (en) 1995-03-10 2001-01-02 Genentech, Inc. Mer receptor activation by gas6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
KR19990028388A (en) 1995-06-30 1999-04-15 피터 지. 스트링거 How to Treat Diabetes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ATE218143T1 (en) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT973550E (en) 1997-04-11 2003-01-31 Searle & Co ANTI-INTEGRINE ANTIBODIES ANTI-INTEGRINA AVB3
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (en) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
CA2328081A1 (en) 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
AU3655899A (en) * 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
CA2341029A1 (en) * 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9913331A (en) 1998-08-25 2001-05-15 Lexigen Pharm Corp Expression and export of angiogenesis inhibitors as immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
AU778939B2 (en) 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins
CN101173295A (en) 1999-05-06 2008-05-07 威克福雷大学 Compositions and methods for identifying antigens which elicit an immune response
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
EP1187852B1 (en) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
ATE316982T1 (en) * 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
DE60122286T2 (en) * 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
PT1719528E (en) * 2000-02-24 2012-01-06 Philogen Spa Compositions and methods for treatment of angiogenesis in pathological lesions
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001088117A2 (en) * 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
BR0112111A (en) * 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
US20040043457A1 (en) 2001-01-18 2004-03-04 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
ATE400030T1 (en) * 2001-02-19 2008-07-15 Merck Patent Gmbh METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY
MXPA03007323A (en) * 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
CA2440221C (en) * 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (en) * 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP3712985B2 (en) 2002-02-22 2005-11-02 アンリツ株式会社 Method for detecting carrier leak adjustment point of quadrature modulator, carrier leak adjustment method, and quadrature modulation apparatus
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
DE10310387B3 (en) 2003-03-07 2004-07-22 Heraeus Electro-Nite International N.V. Measurement sensor determining oxygen activity and other elements in molten metal or slag, includes solid electrolyte tube coated with calcium zirconate and a fluoride
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins

Also Published As

Publication number Publication date
EP1037927B1 (en) 2004-05-19
CA2312188C (en) 2010-06-29
PT1037927E (en) 2004-10-29
US20080311655A1 (en) 2008-12-18
WO1999029732A3 (en) 1999-08-26
CA2693296C (en) 2013-09-10
ATE267215T1 (en) 2004-06-15
US20100015089A1 (en) 2010-01-21
US7576193B2 (en) 2009-08-18
US20050137384A1 (en) 2005-06-23
EP1489100B1 (en) 2016-06-15
EP1489100A3 (en) 2012-06-06
WO1999029732A2 (en) 1999-06-17
US20020193570A1 (en) 2002-12-19
EP1037927A2 (en) 2000-09-27
JP4336452B2 (en) 2009-09-30
ES2590912T3 (en) 2016-11-24
JP2001525423A (en) 2001-12-11
CA2693296A1 (en) 1999-06-17
DE69824039T2 (en) 2005-08-18
US7879319B2 (en) 2011-02-01
JP2009149640A (en) 2009-07-09
US7226998B2 (en) 2007-06-05
AU763719B2 (en) 2003-07-31
DE69824039D1 (en) 2004-06-24
AU1716099A (en) 1999-06-28
US6838260B2 (en) 2005-01-04
DK1037927T3 (en) 2004-09-06
ES2221717T3 (en) 2005-01-01
EP1489100A2 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
CA2312188A1 (en) Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
Gillies et al. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.
DK0673420T3 (en) Mammalian receptors for interleukin 10 (IL-10)
KR950700419A (en) MONOMERIC AND DIMERIC ANTIBODY-FRAGMENT FUSION PROTEINS
AU664801B2 (en) Humanised antibodies
ATE313633T1 (en) EXPRESSION VECTORS ENCODING BISPECIFIC PROTEINS AND METHOD FOR PRODUCING BIOLOGICALLY-ACTIVE BISPECIFIC FUSION PROTEINS IN MAMMAL CELLS
HUP0301102A2 (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
UA41888C2 (en) Fusion protein containing murine or humanized monoclonal antibody mab425 or its fragment directed against tumor cell, method of production, pharmaceutical composition
WO2003087320A3 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
ATE237641T1 (en) BLOOD-FORMING FUSION PROTEIN WITH IL-3 VARIANTS
DE69412614T2 (en) RECOMBINANT DISULFID-STABILIZED POLYPEPTIDES WITH BINDING SPECIFICITY
ATE131871T1 (en) TUMOR NECROSIS FACTOR ALPHA AND BETA RECEPTORS
DE3855536D1 (en) RECEPTORS FOR GROWTH HORMONES
AU639226B2 (en) Recombinant protein receptor
DK0759942T3 (en) Interleukin-15 receptors
ES2149244T3 (en) PROCEDURES FOR PRODUCING PROTEIN C.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181210